PMID- 30588353
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 9
IP  - 2
DP  - 2018 Mar
TI  - Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase 
      Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
PG  - 189-200
AB  - Inhibitors of the epidermal growth factor receptor (EGFR) are important treatment 
      options for non-small cell lung cancer (NSCLC) patients with activating EGFR 
      mutations. Erlotinib, gefitinib, afatinib, and osimertinib are approved for use 
      in NSCLC patients, and several other agents are in clinical development. The 
      objectives of this article are to review the pharmacokinetic and known drug 
      interaction data for EGFR tyrosine kinase inhibitors (TKIs) available for use in 
      NSCLC patients, as well as adverse events (AEs) commonly observed with EGFR-TKI 
      treatment, and to discuss relevant management strategies. The importance of this 
      information for patient care is explored from the perspective of advanced 
      practitioners. Pharmacokinetic, drug-interaction, and safety data are included 
      for EGFR inhibitors approved for NSCLC (erlotinib, gefitinib, afatinib, and 
      osimertinib). Relevant dose modifications and AE management strategies are also 
      reviewed. The interdisciplinary health-care team plays an essential role in 
      patient education, care planning, and medication administration. As such, it is 
      essential that advanced practitioners understand the safety profiles and the 
      potential for drug interactions with EGFR TKIs to ensure patients achieve the 
      maximum benefit from these agents.
FAU - Kucharczuk, Colleen R
AU  - Kucharczuk CR
AD  - Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Ganetsky, Alex
AU  - Ganetsky A
AD  - Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
FAU - Vozniak, J Michael
AU  - Vozniak JM
AD  - Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania at the 
      time of article submission, currently at Merck & Co., Inc, Kenilworth, New 
      Jersey.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180301
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC6302998
EDAT- 2018/12/28 06:00
MHDA- 2018/12/28 06:01
PMCR- 2018/03/01
CRDT- 2018/12/28 06:00
PHST- 2018/12/28 06:00 [entrez]
PHST- 2018/12/28 06:00 [pubmed]
PHST- 2018/12/28 06:01 [medline]
PHST- 2018/03/01 00:00 [pmc-release]
PST - ppublish
SO  - J Adv Pract Oncol. 2018 Mar;9(2):189-200. Epub 2018 Mar 1.